Eton Pharmaceuticals Inc. (ETON) shares declined 10.39% in after-hours on Friday, August 06, 2021, and closed the weekly trading at $5.26 per share. In the regular trading session. ETON’s stock lost 0.34. ETON shares have fallen 13.17% over the last 12 months, and they have moved up 14.20% in the past week. Over the past three months, the stock has lost 25.79%, while over the past six months, it has slid down 40.59%.
Let’s see what are the latest news about the company?
ETON upcoming financial results announcement
Eton Pharmaceuticals, Inc (ETON will release its second-quarter 2021 financial and operating results on Monday, August 16, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (3:30 p.m. CT).
What analysts are expecting?
According to the market expectations, the company may deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021.
According to the Zacks, estimates, the company can report a quarterly loss of $0.14 per share, which represents a year-over-year change of +39.1%. Zack is expecting a revenue of $3.83 million, which is up 19050% from the year-ago quarter.
ETON stock can go up if key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.
ETON acquired Crossject’s ZENEO rights
On June 15, 2021, Eton Pharmaceuticals, Inc (ETON) acquired U.S. and Canadian rights to Crossject’s ZENEO® hydrocortisone needleless autoinjector, which is under development as a rescue treatment for adrenal crisis.
ETON provided an update about Rezipres
On June 15, 2021, Eton Pharmaceuticals, Inc received U.S. Food and Drug Administration (FDA) approval for Rezipres® (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Dehydrated Alcohol Injection NDA rejected by FDA
On May 28, 2021, Eton Pharmaceuticals (ETON) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) related to dehydrated alcohol injection for treating methanol poisoning.
After reviewing the NDA, the FDA has declined to approve it in its present form.
ETON Q1 2021 financial results announcement
On May 13, 2021, Eton Pharmaceuticals, Inc reported financial results for the first quarter ended March 31, 2021.
Q1 2021 financial highlights
- Revenue was $11.9 million for the first quarter of 2021 compared to $0.1 million in Q1 2020.
- General and administrative expenses were $4.1 million inQ1 2021 compared to $2.6 million in Q1 2020.
- Research and development expenses were $0.9 million compared to $6.3 million in the prior-year period.
- it reported a net income of $5.1 million or diluted earnings per share of $0.19 in Q1 2021, compared to a net loss of $9.0 million or a loss of $0.50 per share in the prior-year period.
- As of March 31, 2021, the company had cash and cash equivalents of $25.1 million.
Conclusion
Well, as of this writing, there is no ground for its loss on Friday. we hope that it will commence the new week with a positive mode.
